Syros Pharmaceuticals Financial Health
How is Syros Pharmaceuticals's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: SYRS's short term assets ($252.3M) exceed its short term liabilities ($38.4M).
Long Term Liabilities: SYRS's short term assets ($252.3M) exceed its long term liabilities ($117.1M).
Debt to Equity History and Analysis
Debt Level: SYRS has more cash than its total debt.
Reducing Debt: SYRS's debt to equity ratio has increased from 0% to 31.4% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SYRS has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: SYRS has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 19.4% each year.